Introduction: The crowded U.S. rheumatoid arthritis (RA) market boasts nine different biologics representing five distinct drug classes, including the blockbuster tumor necrosis factor-alpha (TNF…
MARKET OUTLOOK Treatment for PsA typically begins with a cDMARD, but often progresses to a tsDMARD or bDMARD within two years. TNFi are the mainstay of treatment for recently treated…
Rheumatoid arthritis (RA) treatment typically begins with one or more conventional DMARDs, followed by a first-line biologic, usually a TNF-α inhibitor. Patients refractory to one or more TNF-α…
Market Outlook Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA); it is also the only other oral targeted therapy, besides Celgene’s PDE-4 inhibitor, Otezla,…
Market Outlook Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA); it is also the only other oral targeted therapy, besides Celgene’s PDE-4 inhibitor, Otezla,…
MARKET OUTLOOK Treatment of rheumatoid arthritis (RA) is typically initiated with cost-effective conventional DMARDs, such as methotrexate. For RA patients who are refractory to conventional…
Introduction: The moderate to severe rheumatoid arthritis (RA) market is crowded; multiple targeted therapies are available, including nine different branded biologics, a biosimilar, and a small-…
The lucrative EU5 rheumatoid arthritis market is dominated by biologics, including five tumor necrosis factor (TNF)-α inhibitors and four biologics with alternative mechanisms of action. The TNF…
The tumor necrosis factor (TNF) inhibitors have set a high clinical standard for the treatment of psoriatic arthritis (PsA) that is challenging for emerging therapies to surpass. However, several…
Following the European Medicines Agency’s approvals of the PDE-4 inhibitor Otezla and the IL-17 inhibitor Cosentyx for psoriatic arthritis (PsA), treatment of this disease in the EU5 has begun to…
The algorithms for treating psoriatic arthritis (PsA) are unique among rheumatic diseases because most PsA patients receive prior treatment by dermatologists for psoriasis, with many of the same…
Abstract: The mature rheumatoid arthritis (RA) market boasts ten different biologics representing several distinct drug classes, including blockbuster tumor necrosis factor alpha (TNF-α)…
Although TNF-α inhibitors and other RA biologics are generally considered efficacious and safe and adequately control disease in many conventional DMARD-refractory RA patients, therapies that are…
PsA, a disease characterized by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underdiagnosed, and undertreated. Nevertheless, TNF…
Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARDs, such as methotrexate. The U.S. market for conventional DMARD-refractory RA patients is crowded…